Patents by Inventor Anne VERHAGEN

Anne VERHAGEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of FVIII immunogenicity by truncated VWF
    Patent number: 11141466
    Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 12, 2021
    Assignee: CSL Behring Lengnau AG
    Inventors: Anne Verhagen, Sabine Pestel, Thomas Weimer, Marco Hofmann, Huy Huynh, Eugene Maraskovsky
  • METHOD OF TREATING CANCER
    Publication number: 20210292411
    Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.
    Type: Application
    Filed: November 4, 2020
    Publication date: September 23, 2021
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS
  • MODULATION OF FVIII IMMUNOGENICITY BY TRUNCATED VWF
    Publication number: 20200197495
    Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.
    Type: Application
    Filed: June 22, 2018
    Publication date: June 25, 2020
    Inventors: Anne VERHAGEN, Sabine PESTEL, Thomas WEIMER, Marco HOFMANN, Huy HUYNH, Eugene MARASKOVSKY
  • METHOD OF TREATING CANCER
    Publication number: 20190023783
    Abstract: The present disclosure provides computer-implemented methods of organising the marketing of a compound that neutralises BTN2A1.
    Type: Application
    Filed: July 31, 2018
    Publication date: January 24, 2019
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS
  • METHOD OF TREATING CANCER
    Publication number: 20160376364
    Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.
    Type: Application
    Filed: November 28, 2014
    Publication date: December 29, 2016
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS